Skip to main navigation Skip to search Skip to main content

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with nonvisceral or lymph node–only disease

  • Joaquim Bellmunt*
  • , Thomas Powles
  • , Se Hoon Park
  • , Eric Voog
  • , Begona P. Valderrama
  • , Howard Gurney
  • , Anders Ullén
  • , Yohann Loriot
  • , Srikala S. Sridhar
  • , Norihiko Tsuchiya
  • , Cora N. Sternberg
  • , Jeanny B. Aragon-Ching
  • , Daniel P. Petrylak
  • , Miguel A. Climent Duran
  • , Karin Tyroller
  • , Jason Hoffman
  • , Natalia Jacob
  • , Petros Grivas
  • , Shilpa Gupta
  • *Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

9 Downloads (Pure)

Abstract

In the JAVELIN Bladder 100 randomized phase 3 trial (N = 700), avelumab first-line maintenance plus best supportive care (BSC) significantly prolonged overall survival (OS; primary endpoint) and progression-free survival (PFS) versus BSC alone in patients with advanced urothelial carcinoma (aUC) without progression after first-line platinum-based chemotherapy (PBC). Here, we report exploratory analyses of subgroups with nonvisceral metastases at the start of PBC (including bone metastases) or lymph node–only disease at randomization. The median OS with avelumab versus control in patients with nonvisceral metastases (n = 318) was 31.4 versus 17.1 mo (hazard ratio [HR], 0.60 [95% confidence interval {CI}, 0.45–0.79]), and in patients with lymph node–only disease (n = 102), it was 31.9 versus 22.7 mo (HR, 0.86 [95% CI, 0.51–1.47]). In patients with nonvisceral metastases, prolonged OS was observed with avelumab irrespective of the response to PBC or PBC regimen received. PFS analyses favored avelumab over control in all the subgroups. Incidences of avelumab-related adverse events were similar across the subgroups. Limitations include small sample sizes and the exploratory nature of analyses. Overall, exploratory analyses suggest that in first-line PBC-treated patients without progression, avelumab maintenance is effective and has a manageable toxicity profile in patients with aUC who have nonvisceral metastases or lymph node–only disease.

Original languageEnglish
Pages (from-to)331-338
Number of pages8
JournalEuropean Urology
Volume88
Issue number4
Early online date3 Jun 2025
DOIs
Publication statusPublished - Oct 2025

Bibliographical note

Copyright the European Association of Urology Copyright the Author(s) 2025. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

  • Anti–PD-L1
  • Avelumab
  • Bladder cancer
  • Clinical trial
  • Immune checkpoint inhibitor
  • Immunotherapy
  • Lymph node
  • Maintenance
  • Nonvisceral metastases
  • Urothelial carcinoma

Fingerprint

Dive into the research topics of 'Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with nonvisceral or lymph node–only disease'. Together they form a unique fingerprint.

Cite this